Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 6, 2011, Pages 1273-1279

  Steele, N L ^a,b   Plumb, J A ^b   Vidal, L ^c   Tjornelund J ^d   Knoblauch, P ^d   Buhl Jensen, P ^d   Molife, R ^c   Brown, R ^b   De Bono, J S ^c   Evans, T R J ^a,b  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d BioAlliance Pharma   (France)

Author keywords

Bioavailability; Histone deacetylase; Pharmacodynamics; Pharmacokinetics; Phase 1 trial

Indexed keywords

BELINOSTAT; HISTONE H4;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; COLORECTAL CANCER; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG TOLERABILITY; ESOPHAGUS CANCER; FATIGUE; FEASIBILITY STUDY; FEMALE; HISTONE ACETYLATION; HUMAN; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; LYMPHOCYTE COUNT; MALE; MELANOMA; NAUSEA; OVARY CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; SARCOMA; SIDE EFFECT; SINGLE DRUG DOSE; STOMACH CANCER; THYMOMA; VOMITING;

ACETYLATION; ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; FEASIBILITY STUDIES; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; HYDROXAMIC ACIDS; LEUKOCYTES, MONONUCLEAR; MIDDLE AGED;

EID: 79959611523     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1419-5     Document Type: Article

References (15)

1. Marks PA, Richon VM, Rifkind RA (2000) Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92:1210-1216 (Pubitemid 30627729)
2. Van Lint C, Emiliani S, Verdin E (1996) The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Express 5:245-253
3. Gu W, Roeder RG (1997) Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90:595-606 (Pubitemid 27357952)
4. Chan HM, Krstic-Demonacos M, Smith L et al (2001) Acetylation control of the retinoblastoma tumour-suppressor protein. Nat Cell Biol 3:667-674 (Pubitemid 32624423)
5. Plumb JA, Finn PW, Williams RJ et al (2003) Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2:721-728
6. Steele NL, Plumb JA, Vidal L et al (2008) A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 14:804-810 (Pubitemid 351231163)
7. Yoshida M, Kijima M, Akita M, Beppu T (1990) Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265:17174-17179
8. Tumber A, Collins LS, Petersen KD et al (2007) The histone deacetylase inhibitor PXD101 synergises with 5-Fluorouracil to inhibit colon cancer cell growth in vitro and in vivo. Cancer Chemother Pharmacol 60:275-283 (Pubitemid 46742543)
9. Qian X, LaRochelle WJ, Ara G et al (2006) Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther 5:2086-2095 (Pubitemid 44336581)
10. Qian X, Ara G, Mills E et al (2008) Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer. Int J Cancer 122:1400-1410 (Pubitemid 351287242)
11. Siu LL, Pili R, Duran I et al (2008) Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J Clin Oncol 2008:1940-1947
12. Ryan QC, Headlee D, Acharya M et al (2005) Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 23:3912-3922 (Pubitemid 46218694)
13. Kelly WK, O'Connor OA, Krug LM et al (2005) Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23:3923-3931 (Pubitemid 46218695)
14. Rubin EH, Agrawal NG, Friedman EJ et al (2006) A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer. Clin Cancer Res 12:7039-7045 (Pubitemid 44974501)
15. Acharya MR, Karp JE, Sausville EA et al (2006) Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer. Invest New Drugs 24:367-375 (Pubitemid 43876072)